Japan MHLW Establishes New Flu Policy Guidance
This article was originally published in PharmAsia News
Executive Summary
The Minister of Health, Labor and Welfare Yoichi Masuzoe June 19 announced a new policy to prepare for the second wave of flu infection, estimated to arrive during the fall to winter session. The new policy calls for patients with light flu symptoms to rest at home, and all medical facilities should treat new flu cases. MHLW also announced a halt in seasonal flu vaccine manufacturing and a start of new flu vaccine production from mid-July. The Minister estimates that within the year, four Japanese vaccine makers will produce vaccines for 2.5 million people, and new flu vaccinations will be available in October. Japan has yet to decide who will be among the first to be vaccinated. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.